Group 1 - The core revenue growth is driven by the medical aesthetics business, which generated approximately RMB 1.485 billion in revenue, a year-on-year increase of about 99.6% [1] - The core product, Letibao, expanded its coverage to over 8,000 medical beauty institutions and 1,500 key institutions, contributing to steady revenue growth [1] - The innovative drugs and other pharmaceuticals generated approximately RMB 176 million, a year-on-year increase of about 206.3%, primarily due to increased sales of diabetes medications [1] Group 2 - The year 2026 is critical for the company’s strategic transformation and high-quality development, marking the beginning of its three-year strategic plan [2] - The company aims to become a benchmark enterprise in the Chinese medical aesthetics industry by focusing on compliance, growth in regenerative materials and collagen protein, and personalized anti-aging solutions [2] - The core strategy includes deepening dual-driven growth, releasing synergistic value, accelerating global layout, and enhancing capital efficiency [2] Group 3 - The total revenue for the year ending December 31, 2025, was approximately RMB 2.618 billion, a year-on-year increase of about 37.7% [3] - Gross profit was approximately RMB 1.802 billion, a year-on-year increase of about 45.1%, while overall research and development expenses were approximately RMB 291 million, a decrease of 38.5% [3] - The company reported a profit attributable to shareholders of approximately RMB 180 million, turning a profit compared to the previous year, with basic earnings per share of 1.97 cents [3]

Core Insights - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - The financial performance during this period is influenced by several factors, including significant growth in the medical aesthetics business, the maturation of innovative drug operations, a narrowing decline in the generic drug sector, and a strong financial position with ample cash reserves [1] Group 1 - The medical aesthetics business is projected to grow at a rate of 50%-60% compared to the same period last year [1] - The innovative drug segment is entering a harvest phase, with reduced R&D expenses, a steady stream of new product approvals, and successful commercialization efforts [1] - The decline in the generic drug business is narrowing year by year [1] - The company maintains a robust financial status with substantial cash on hand [1] Group 2 - From January 2024 to July 2025, the company has received approvals for 41 new medical aesthetics and pharmaceutical products, including nine medical aesthetics products and 32 pharmaceutical products [2] - Key products include self-developed medical devices and innovative drugs, which are expected to drive future revenue and profit growth [2] - The company is confident about its future development prospects due to the simultaneous launch of numerous significant new products [2]

Group 1 - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - Key factors influencing the financial performance include a high growth rate in the medical aesthetics business, with an increase of 50%-60% compared to the same period last year [1] - The innovative drug business is entering a harvest period, with a gradual reduction in R&D expenses and a steady stream of new product approvals contributing to revenue growth [1] Group 2 - A total of 41 new medical aesthetics and pharmaceutical products have been approved for market launch from January 2024 to July 2025, including nine medical aesthetics products and 32 pharmaceutical products [2] - The launch of multiple heavyweight new products is expected to provide strong momentum for future revenue and profit growth, instilling confidence in the company's development prospects [2]

Group 1 - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - Key factors influencing the financial performance include a high growth rate in the medical aesthetics business, with an expected increase of 50%-60% compared to the same period last year [1] - The innovative drug business is entering a harvest phase, with reduced R&D expenses and a steady stream of new product approvals contributing to revenue growth [1] - The decline in the generic drug business is narrowing year by year, indicating improved performance in this segment [1] - The company's financial position is robust, with ample cash reserves [1] Group 2 - From January 2024 to July 2025, the company has 41 new medical aesthetics and pharmaceutical products approved for launch, including nine medical aesthetics products and 32 pharmaceutical products [2] - Notable products include self-developed medical devices and innovative drugs, which are expected to drive significant future revenue and profit growth [2] - The company is confident about its future development prospects due to the simultaneous launch of multiple heavyweight new products [2]